| |
Survival
|
p-value
|
|---|
| |
at 12 months (%)
|
at 24 months (%)
|
univariate Analysis
|
multivariate Analysis
|
|---|
|
Age
|
|
≤ 65 years
|
56
|
19
| | |
|
> 65 years
|
80
|
27
|
0.676
| |
|
Gender
|
|
Female
|
80
|
20
| | |
|
Male
|
65
|
23
|
0.629
| |
|
Karnofsky performance status
|
|
> 80%
|
75
|
30
| | |
|
≤ 80%
|
55
|
10
|
0.041
|
0.077
|
|
UICC stage
|
|
III
|
64
|
21
| | |
|
IV
|
100
|
33
|
0.537
| |
|
T category
|
|
1–2
|
67
|
0
| | |
|
3–4
|
68
|
28
|
0.395
| |
|
N category
|
|
0–1
|
33
|
0
| | |
|
2–3
|
71
|
25
|
0.299
| |
|
Histology
|
|
Squamous cell carcinoma
|
69
|
25
| | |
|
Non- Squamous cell carcinoma
|
67
|
20
|
0.935
| |
|
Tobacco consumption (PY)
|
|
0
|
75
|
25
| | |
|
20–40
|
50
|
12,50
| | |
|
> 40
|
73
|
27
|
0.758
| |
|
Grading
|
|
Moderately differentiated
|
50
|
50
| | |
|
Poorly differentiated
|
67
|
19
| | |
|
anaplastic
|
100
|
50
|
0.758
| |
|
PD-L1 expression
|
|
0%
|
86
|
29
| | |
|
≥ 1%
|
50
|
19
|
0.048
|
0.648
|
|
CD8+ TILs density
|
|
≤ 40%
|
70
|
40
| | |
|
> 40%
|
61
|
17
|
0.055
| |
|
TIME type
|
|
I
|
100
|
60
| | |
|
II
|
50
|
20
| | |
|
III
|
71
|
14
| | |
|
IV
|
40
|
20
|
0.05
|
0.048
|
